Cefixime Cure Rate for Gonorrhea

Historical Efficacy Data

The CDC guidelines recommend cefixime 400 mg orally as a single dose, achieving a cure rate of 97.4% for uncomplicated urogenital and anorectal gonorrhea, making it an effective oral alternative to intramuscular ceftriaxone 1, 2
The CDC established cefixime 400 mg as a recommended first-line regimen based on clinical trial data showing a 97.4% cure rate for uncomplicated urogenital and anorectal infections 1, 2

Cefixime 400 mg does not provide as high or sustained bactericidal blood levels as ceftriaxone 125 mg IM, with cefixime maintaining free drug concentrations above the MIC90 for 22-50 hours 1, 2, 4

Oral administration of cefixime eliminates the need for injection, improving patient acceptance and ease of delivery 1, 2

Cefixime was effective against resistant strains in earlier studies, but ongoing surveillance is critical as cephalosporin resistance patterns evolve 1, 2
Cefixime does not treat concurrent chlamydial infection, which persists in at least 50% of co-infected patients, and requires co-treatment with azithromycin or doxycycline 1, 2
These cure rates apply only to uncomplicated urogenital, anorectal, and pharyngeal infections, and for disseminated gonococcal infection or other complications, parenteral ceftriaxone is required 1, 2

Ceftriaxone 125 mg IM achieves 99.1% cure rates and provides superior pharmacodynamics, making it the preferred choice when injection is feasible, but cefixime 400 mg remains a valid choice with documented efficacy above the 95% threshold for first-line therapy 1, 2
For pharyngeal gonorrhea, cefixime shows 91% efficacy, which is acceptable but less robust than urogenital sites 3